NCT07066839

Chrysin Bioavailability and Safety

Pharmacokinetics and Bioavailability of Three Chrysin Formulations in Healthy Adults

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 18 (actual)
• Sponsor: Isura · Academic / Other
• Sex: All
• Age: 21 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This study seeks to evaluate and compare the pharmacokinetics of a micellar chrysin formulation (LipoMicel Chrysin) with that of a non-micellar chrysin formulation as well as a standard/unformulated chrysin supplement. The study also seeks to determine the short-term effects and safety of daily oral supplementation of LipoMicel Chrysin in healthy adult volunteers over a 30-day study period.

Conditions

• Bioavailability and Pharmacokinetics
• Safety After Oral Intake

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	LipoMicel Chrysin	A maximum single oral dose of 1000 mg chrysin
DIETARY_SUPPLEMENT	Non-Micellar Chrysin	A maximum single oral dose of 1000 mg chrysin
DIETARY_SUPPLEMENT	Standard/Unformulated Chrysin	A maximum single oral dose of 1000 mg chrysin

Timeline

• Start date: 2024-12-05
• Primary completion: 2025-02-21
• Completion: 2025-04-02
• First posted: 2025-07-15
• Last updated: 2025-07-15

Locations

1 site across 1 country: Canada